<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; First Trust Large Cap Gr Opp AlphaDEX</title>
	<atom:link href="http://www.stockbloghub.com/tag/first-trust-large-cap-gr-opp-alphadex/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CVS) Management Churn at CVS Caremark</title>
		<link>http://www.stockbloghub.com/2012/04/04/cvs-management-churn-at-cvs-caremark-analyst-blog/97427</link>
		<comments>http://www.stockbloghub.com/2012/04/04/cvs-management-churn-at-cvs-caremark-analyst-blog/97427#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:54:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAI]]></category>
		<category><![CDATA[AirTran Holdings Inc]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Pacific Booker Minerals Inc.]]></category>
		<category><![CDATA[PBM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97427</guid>
		<description><![CDATA[CVS Caremark Corporation (CVS) recently announced a change in top management. According to the company’s design, effective September 1, 2012, the present EVP and Chief Operating Officer of the Pharmacy Benefit Management (PBM) business, Jon Roberts will replace Per Lofberg, the President of the PBM business. However, Robert will continue to report to Lofberg who extended his employment agreement with the company till December 2013. September onwards, Lofberg will serve as the chairman of the PBM and look after the business strategies of PBM, new business development, client relationship management and retention and will directly report to Larry Merlo, the President and CEO of CVS Caremark. Rhode Island-based CVS Caremark is a combination of a PBM as well as retail drug chain. In terms of contractual arrangements with large plan ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/cvs-management-churn-at-cvs-caremark-analyst-blog/97427/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CVS) CVS Caremark Corporation Ordered by FTC to Settle Claims</title>
		<link>http://www.stockbloghub.com/2012/01/13/cvs-cvs-caremark-corporation-ordered-by-ftc-to-settle-claims/90162</link>
		<comments>http://www.stockbloghub.com/2012/01/13/cvs-cvs-caremark-corporation-ordered-by-ftc-to-settle-claims/90162#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:05:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Pacific Booker Minerals Inc.]]></category>
		<category><![CDATA[PBM]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90162</guid>
		<description><![CDATA[Recently CVS Caremark Corporation (CVS) was asked by the Federal Trade Commission (FTC) to pay $5 million to settle all claims related to the company’s misrepresentation of prices of certain Medicare Part D prescription drugs at CVS Caremark and Walgreen (WAG)  pharmacies. The FTC alleged that from 2007 through November 2008, CVS Caremark’s subsidiary RxAmerica posted wrong prices on its website for prescription drugs including medications to treat epilepsy and symptoms of breast cancer. It also provided incorrect prices for posting to Plan Finder and third-party websites. The cases were extremely misleading for several seniors and disabled customers as the posted prices were 10 times below the actual prices of the drugs. This fake interpretation encouraged patients to opt for RxAmerica’s plans, which later pushed them into the &#8220;doughnut hole” ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/cvs-cvs-caremark-corporation-ordered-by-ftc-to-settle-claims/90162/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings-Orchid Deal Evinces FTC Nod</title>
		<link>http://www.stockbloghub.com/2011/12/09/lh-laboratory-corporation-of-america-holdings-orchid-deal-evinces-ftc-nod/88339</link>
		<comments>http://www.stockbloghub.com/2011/12/09/lh-laboratory-corporation-of-america-holdings-orchid-deal-evinces-ftc-nod/88339#comments</comments>
		<pubDate>Fri, 09 Dec 2011 20:43:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[ORCH]]></category>
		<category><![CDATA[Orchid Cellmark Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88339</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) received the much awaited nod from the US Federal Trade Commission (FTC) for the proposed acquisition of Orchid Cellmark (ORCH). The FTC nod comes with the rider that LabCorp will have to hive off certain assets of Orchid’s US government paternity business following completion of the transaction. This would reduce the “anti-competitive impact” of the proposed merger, according to the federal agency. LabCorp has agreed to sell those assets to DNA Diagnostics Center, an Ohio based privately held provider of DNA paternity testing. The pending issue with FTC dates back to May 2011. The company’s tender offer for Orchid is scheduled to expire today, unless extended further. LabCorp had decided in April 2011 to acquire Orchid for $2.80 per share, coming to a total ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/lh-laboratory-corporation-of-america-holdings-orchid-deal-evinces-ftc-nod/88339/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings Extends Orchid Bid Again</title>
		<link>http://www.stockbloghub.com/2011/12/07/lh-laboratory-corporation-of-america-holdings-extends-orchid-bid-again/88036</link>
		<comments>http://www.stockbloghub.com/2011/12/07/lh-laboratory-corporation-of-america-holdings-extends-orchid-bid-again/88036#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[ORCH]]></category>
		<category><![CDATA[Orchid Cellmark Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88036</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) has once again extended the tender offer for Orchid Cellmark (ORCH) until December 9, 2011. The company had earlier extended the tender offer to November 30. In May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction. LabCorp is cooperating with the FTC on this issue. To date, about 88.2% of the outstanding shares of Orchid have been tendered. LabCorp had decided in April 2011 to acquire Orchid Cellmark for $2.80 per share, coming to a total consideration of $85.4 million, all in cash. After taking into account Orchid Cellmark’s cash balance, LabCorp’s net payable comes to $65.6 million. Orchid Cellmark provides DNA testing services targeted towards forensic and family relationship applications on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/lh-laboratory-corporation-of-america-holdings-extends-orchid-bid-again/88036/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MHS) Medco Analyst Maintains Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/12/mhs-medco-analyst-maintains-shares-at-neutral-2/86959</link>
		<comments>http://www.stockbloghub.com/2011/11/12/mhs-medco-analyst-maintains-shares-at-neutral-2/86959#comments</comments>
		<pubDate>Sat, 12 Nov 2011 21:46:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FEP]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[Franklin Electronic Publishers Inc]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86959</guid>
		<description><![CDATA[Recently, we reiterated our Neutral recommendation on Medco Health (MHS) with a target price of $56.00. During the third quarter of fiscal 2011, Medco reported adjusted EPS of $1.07, beating the Zacks Consensus Estimate by 2 cents and 12.6% higher than the year-ago quarter level. Revenues increased 4.1% year over year to $17.0 billion in the quarter, in line with the Zacks Consensus Estimate. The increase in revenue was primarily driven by contributions from significant client wins coupled with higher prices charged for branded drugs, partially offset by higher volumes of lower-priced generic drugs. In fiscal 2010, Medco’s top ten clients (based on revenues) contributed approximately 47% to net revenues. Its largest client, UnitedHealth (UNH) accounted for 17% of net revenues. However, in July 2011, Medco failed to renew its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/12/mhs-medco-analyst-maintains-shares-at-neutral-2/86959/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MHS) Medco Health Solutions and United Drug Terminate Joint Venture</title>
		<link>http://www.stockbloghub.com/2011/10/20/mhs-medco-health-solutions-and-united-drug-terminate-joint-venture/85401</link>
		<comments>http://www.stockbloghub.com/2011/10/20/mhs-medco-health-solutions-and-united-drug-terminate-joint-venture/85401#comments</comments>
		<pubDate>Thu, 20 Oct 2011 14:52:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FEP]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[Franklin Electronic Publishers Inc]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85401</guid>
		<description><![CDATA[Following the termination of the pan-European joint venture between Medco Health Solutions (MHS) and Germany-based Celesio AG, Dublin-based United Drug Plc recently decided to exit from its UK homecare partnership with Medco. As per the terms of the deal, Medco will own 100% interest in this project following the acquisition of United Drug&#8217;s 50% stake. The transaction is expected to be completed by November, 2011. However, the financial and other terms of the termination agreement remain disclosed. The joint venture, which came into existence in 2009, focused on the pharmacy homecare market in UK by providing a high level of service to patients with chronic and complex conditions and supporting the National Health Service (NHS) initiatives. We expect this move to be a hindrance for Medco in achieving its goal of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/20/mhs-medco-health-solutions-and-united-drug-terminate-joint-venture/85401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FTC) Medco Health Solutions and Express Script Asked for More Information from Federal Trade Commission</title>
		<link>http://www.stockbloghub.com/2011/09/12/ftc-medco-health-solutions-and-express-script-asked-for-more-information-from-federal-trade-commission/82626</link>
		<comments>http://www.stockbloghub.com/2011/09/12/ftc-medco-health-solutions-and-express-script-asked-for-more-information-from-federal-trade-commission/82626#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:26:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FEP]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[Franklin Electronic Publishers Inc]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82626</guid>
		<description><![CDATA[Recently, Federal Trade Commission (FTC) requested both Medco Health Solutions (MHS) and Express Script (ESRX) to submit additional information regarding the pending acquisition deal. Under the current circumstances, the completion of the proposed acquisition can get postponed by approximately 30 days. Despite the uncertainty regarding the delay, Medco anticipates to close the deal by the first half of 2012. However, the deal is also subject to approval of the stockholders of both Express Scripts and Medco. Earlier, in July 2011, Medco announced that it will be acquired by Express Scripts for $29.1 billion in cash and stock. As per the terms of the agreement, each shareholder of Medco will receive $28.80 in cash and 0.81 shares of Express Scripts, representing a total value of $71.36 per Medco share. With the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/ftc-medco-health-solutions-and-express-script-asked-for-more-information-from-federal-trade-commission/82626/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FTC) Graco Gets Federal Trade Commission Request</title>
		<link>http://www.stockbloghub.com/2011/07/07/ftc-graco-gets-federal-trade-commission-request/78528</link>
		<comments>http://www.stockbloghub.com/2011/07/07/ftc-graco-gets-federal-trade-commission-request/78528#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:04:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[GGG]]></category>
		<category><![CDATA[Graco Inc]]></category>
		<category><![CDATA[Hi-Shear Technology Corporation]]></category>
		<category><![CDATA[HSR]]></category>
		<category><![CDATA[Illinois Tool Works Inc.]]></category>
		<category><![CDATA[ITW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78528</guid>
		<description><![CDATA[The antitrust regulators, the Federal Trade Commission (FTC) served a request on Graco Inc. (GGG) for additional information on the company’s proposed acquisition of finishing businesses of Illinois Tool Works Inc. (ITW). This acquisition is being investigated under the FTC’s Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, scrutinizing whether the proposed transaction is in compliance with the antitrust laws of the United States. Management stated that the company intends to obtain the FTC’s assent for the merger at the earliest and thus, Graco will cooperate with the FTC. As per the HSR Act, Graco has to wait for a period of 30 days after complying with the request. However, this period can be concluded earlier by the FTC. In April, Graco announced the acquisition of the finishing businesses of Illinois ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/ftc-graco-gets-federal-trade-commission-request/78528/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Apple Eyes Nortel Assets</title>
		<link>http://www.stockbloghub.com/2011/06/24/aapl-apple-eyes-nortel-assets/77412</link>
		<comments>http://www.stockbloghub.com/2011/06/24/aapl-apple-eyes-nortel-assets/77412#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:03:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77412</guid>
		<description><![CDATA[Apple Inc. (AAPL) recently received The Federal Trade Commission’s (FTC) approval to bid for the intellectual properties of the Canadian telecom equipment manufacturer, Nortel Network. The nod from the antitrust regulators is a positive for Apple as it has been interested to buy the patents relating to the 4G and Long Term Evolution (LTE) technologies. Apart from Apple, Google Inc. (GOOG) has also been eyeing these technologies. Given the inherent advantages compared to the conventional 3G technology, 4G has gained tremendous popularity among the mobile companies, as 4G not only speeds up the data transfer rate but also reduces transmission error. The technology is more secure than 3G, and uses Internet Protocol address system similar to Internet. In the United States, there are two major systems using 4G mobile technology. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/aapl-apple-eyes-nortel-assets/77412/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LH) Laboratory Corporation of America Holdings Extends Orchid Tender Offer</title>
		<link>http://www.stockbloghub.com/2011/06/19/lh-laboratory-corporation-of-america-holdings-extends-orchid-tender-offer/76735</link>
		<comments>http://www.stockbloghub.com/2011/06/19/lh-laboratory-corporation-of-america-holdings-extends-orchid-tender-offer/76735#comments</comments>
		<pubDate>Sun, 19 Jun 2011 13:34:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[ORCH]]></category>
		<category><![CDATA[Orchid Cellmark Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76735</guid>
		<description><![CDATA[Laboratory Corporation of America Holdings (LH) has decided to extend the tender offer for Orchid Cellmark (ORCH) till July 15, 2011. Earlier, in May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction. LabCorp is cooperating with the FTC on this issue. Till date about 88.2% of the outstanding shares of Orchid have been tendered. In April, LabCorp had decided to acquire Orchid Cellmark for $2.80 per share in cash or a total $85.4 million. After taking into account Orchid Cellmark’s cash balance LabCorp’s net payable comes to $65.6 million. Orchid Cellmark provides DNA testing services targeted towards forensic and family relationship applications on a global basis. Based on this deal, LabCorp will be able to develop a command ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/lh-laboratory-corporation-of-america-holdings-extends-orchid-tender-offer/76735/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INTC) Intel Agrees to Tough Litigation Settlement with Advanced Micro Devices</title>
		<link>http://www.stockbloghub.com/2009/12/14/intc-intel-agrees-to-tough-litigation-settlement-with-advanced-micro-devices/22726</link>
		<comments>http://www.stockbloghub.com/2009/12/14/intc-intel-agrees-to-tough-litigation-settlement-with-advanced-micro-devices/22726#comments</comments>
		<pubDate>Mon, 14 Dec 2009 17:08:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Broad Line]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[NVDA]]></category>
		<category><![CDATA[NVIDIA Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22726</guid>
		<description><![CDATA[Intel Corp (INTC) has paid Advanced Micro Devices (AMD) the agreed $1.25 billion to settle long-standing disputes between the two chipmakers. This takes care of the AMD lawsuit that was slated to come up for trial early next year, does away with the x86 dispute, imposes restrictions on Intel regarding its competitive behavior and seeks arbitration in the event the companies are unable to resolve any issue mutually. The payment to AMD follows the $1.45 billion in fines paid to the European Commission as penalty for anti-competitive practices. Of course, Intel is appealing the case. We are a bit concerned about the amount of cash Intel is dishing out. While parting with these amounts may not cramp its style (the company generated over $4 billion in the last quarter itself), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/intc-intel-agrees-to-tough-litigation-settlement-with-advanced-micro-devices/22726/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACI) Arch Coal Extends Credit Line</title>
		<link>http://www.stockbloghub.com/2009/09/01/aci-arch-coal-extends-credit-line/14009</link>
		<comments>http://www.stockbloghub.com/2009/09/01/aci-arch-coal-extends-credit-line/14009#comments</comments>
		<pubDate>Tue, 01 Sep 2009 17:28:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Industrial Metals & Minerals]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[First Trust Large Cap Gr Opp AlphaDEX]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[Rio Tinto plc]]></category>
		<category><![CDATA[RTP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14009</guid>
		<description><![CDATA[Arch Coal (ACI) recently extended the size and maturity of its senior secured revolving credit facility. The existing drawing limit under the credit line was raised to $860 million from $800 million through June 2011. From June 2011, the company will have borrowing right of $763 million through March 2013, which may further be raised up to $800 million. The credit line extension will strengthen Arch Coal’s liquidity position and provide greater financial flexibility to pursue attractive growth opportunities going forward. Last week, the company obtained clearance from the Federal Trade Commission (FTC) for acquiring the Jacobs Ranch mine in Wyoming from Rio Tinto (RTP). The $761 million deal will give Arch Coal control over around 381 million tons of high-grade, low-cost coal reserves adjacent to its Black Thunder mine ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/aci-arch-coal-extends-credit-line/14009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

